Shopping Cart
- Remove All
Your shopping cart is currently empty
Dihydroevocarpine (1-methyl-2-tridecylquinolin-4-one) induces AML cytotoxicity, apoptosis and G0/G1 blockade, and inhibits tumor growth by inhibiting mTORC1/2 activity and the mTOR pathway in an acute myeloid leukemia (AML) xenograft model.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $54 | In Stock | |
| 5 mg | $129 | In Stock | |
| 10 mg | $198 | In Stock | |
| 25 mg | $320 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $142 | In Stock |
| Description | Dihydroevocarpine (1-methyl-2-tridecylquinolin-4-one) induces AML cytotoxicity, apoptosis and G0/G1 blockade, and inhibits tumor growth by inhibiting mTORC1/2 activity and the mTOR pathway in an acute myeloid leukemia (AML) xenograft model. |
| Targets&IC50 | CCRF-CEM cells:14.08 μM, CEM/ADR5000 cells:33.14 μM |
| In vitro | Dihydroevocarpine exhibits moderate in vitro cytotoxicity against CCRF-CEM and CEM/ADR5000 leukemia cell lines, with IC₅₀ values of 14.08 μM and 33.14 μM, respectively. [1] |
| In vivo | BALB/C nude mice bearing subcutaneous HL-60 leukemia cells were treated with intraperitoneal injections of Dihydroevocarpine (10 mg/kg/day) for 20 days, resulting in a significant antitumor effect.[2] |
| Synonyms | 1-methyl-2-tridecylquinolin-4-one |
| Molecular Weight | 341.53 |
| Formula | C23H35NO |
| Cas No. | 15266-35-0 |
| Smiles | O=C1C=C(N(C=2C=CC=CC12)C)CCCCCCCCCCCCC |
| Relative Density. | 0.964 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 10 mg/mL (29.28 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.93 mM), Suspension. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.